Neoadjuvant Atezolizumab Safe in Resectable Lung Cancer ...Middle East

Medscape - News
In the LCMC3 study, patients received 1200 mg of neoadjuvant atezolizumab IV every 3 weeks for two cycles followed by resection between 30 and 50 days from the first cycle. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Neoadjuvant Atezolizumab Safe in Resectable Lung Cancer )

Apple Storegoogle play

Also on site :

Most viewed in News


Latest News